| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
|
Ann Intern Med
|
2014
|
3.48
|
|
2
|
Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
|
Clin Infect Dis
|
2015
|
1.12
|
|
3
|
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals.
|
J Acquir Immune Defic Syndr
|
2013
|
1.05
|
|
4
|
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.
|
AIDS
|
2015
|
1.05
|
|
5
|
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
|
J Infect Dis
|
2015
|
0.99
|
|
6
|
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
|
Clin Infect Dis
|
2016
|
0.94
|
|
7
|
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
|
Clin Infect Dis
|
2015
|
0.86
|
|
8
|
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia.
|
Open Forum Infect Dis
|
2015
|
0.80
|
|
9
|
Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.
|
Clin Med Rev Ther
|
2011
|
0.80
|
|
10
|
Grayscale Ultrasound Texture Features of Carotid and Brachial Arteries in People With HIV Infection Before and After Antiretroviral Therapy.
|
J Am Heart Assoc
|
2022
|
0.75
|
|
11
|
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
|
J Infect Dis
|
2016
|
0.75
|
|
12
|
Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.
|
Open Forum Infect Dis
|
2016
|
0.75
|